A novel disposable sensor based on reduced graphene oxide-polyaniline (rGO-PANi) for detection of loop-mediated-isothermal-amplification (LAMP) products.

In this work, the polyaniline/reduced graphene oxide (PANi/rGO) bilayer was directly electrodeposited on carbon screen‐printed electrodes (SPE). Some details in growth of PANi/rGO bilayer were revealed from cyclic voltammograms and X‐ray photoelectron spectra. The growth of stacked rGO film at high compactness on the electrode surface is mainly accompanied with reduction of epoxy functional groups at basal planes of graphitic flakes. The as‐grown rGO layer with abundent hydroxyl functional groups at basal planes is preferable to attract intrinsic fibrillar‐like PANi polymer chains in protonated aqueous media. The as‐prepared PANi/rGO hybrid bilayer has shown good conductivity, high porosity, good adhesion to biomolecules, and fast electron transfer rate (increased by 3.8 times). Herein, PANi/rGO film has been further utilized to develop disposable acetylcholinesterase sensors able to detect acetylthiocholine (ATCh) with apparent Michaelis ‐ Menten constant of 0.728 mM. These sensors provide a very promising technical solution for in‐situ monitoring acetylthiocholine level in patients with neuro‐diseases and determination of neuro‐toxins such as sarin and pesticides.

Drug-drug interaction is one of the drug-related problems that can reduce therapeutic efficacy or increase the risk of undesirable effects. Subjects and methods: interventional study design with before-after comparison. In the pre-intervention period, we retrospectively carried out all electronic prescriptions and medical records of inpatients treated from 01/11/2021 to 31/01/2022. In the post-intervention period, we prospectively performed monitoring reports on the drug-drug interaction warning system and medical records of inpatients from 01/02/2022 to 31/03/2022. Results: The proportion of patients exposed to drug-drug interactions (DDIs) decreased significantly from 4.27% in the pre-intervention period to 3.56% in the post-intervention period (p<0.05). There were no medical records with contraindicated DDIs in the post-intervention period. The percentage of patients for contraindication DDIs with conditions determined to patients with the condition was 39.33% and 27.59%, respectively, in the pre-and post-intervention phases. Medical records rate with major DDIs decreased significantly in the post-intervention period (2.95% vs 3.68%; p<0.05). Conclusion: Clinical decision support systems with drug-drug interaction warnings and clinical pharmacy activities help to reduce the frequency of DDIs. The results show that the combination of these two measures initially brings about effective DDIs management in hospitals.

Anti-influenza-A drugs targeting viral neuraminidase have been in use for two decades. In this study, the quantitative structure-activity relationships (QSAR) of oseltamivir derivatives as influenza neuraminidase (IN) inhibitors have been explored using the Monte Carlo method based on the target function involving the index of the ideality of correlation. Three best-obtained models showed appropriate performance with R2 values of training and test sets ranging from 0.71 to 0.86, respectively. Based on the structural information extracted from the models, new inhibitors were designed and predicted for IN activities. Finally, protein docking was applied to confirm their target binding ability. Keyword: Anti-influenza A; neuramidase inhibitor; drug design; QSAR; docking.